Skip to main content
SpringerLink
Log in

Naltrexone/bupropion increases risk of serious AEs

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Onakpoya IJ, et al. Naltrexone-bupropion (Mysimba(R)) in management of obesity: a systematic review and meta-analysis of unpublished clinical study reports. British Journal of Clinical Pharmacology : 9 Jan 2020. Available from: URL: http://doi.org/10.1111/bcp.14210

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Naltrexone/bupropion increases risk of serious AEs. Reactions Weekly 1788, 8 (2020). https://doi.org/10.1007/s40278-020-74131-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-74131-8

Search

Navigation